# Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

Federal grant opportunity, via Kontrakk.

- **Agency:** National Institutes of Health
- **Opportunity number:** PAR-25-226
- **Status:** posted
- **Opens:** November 22, 2024
- **Closes:** November 19, 2026
- **CFDA:** 93.242
- **View on Kontrakk:** https://kontrakk.com/grants/357343

## Description

No description provided.